Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
NCT ID: NCT02022020
Last Updated: 2017-01-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
220 participants
OBSERVATIONAL
2014-01-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
NCT02149303
Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
NCT01721837
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
NCT01976507
Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
NCT02514304
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
NCT00846807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of Atrial Fibrillation (AF);
* Documentation that the patient had an acute GI and/or GU bleeding event and having taken at least one dose of dabigatran prior to the event.
Exclusion Criteria
* Documentation that the patient was taking dabigatran with other oral anticoagulant;
* Documentation of the patient receiving thrombolytic therapy prior to the event;
* Documentation that the patient was enrolled in an investigational clinical trial at the time of the event;
* Medical record was not available.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Aurora, Colorado, United States
Boehringer Ingelheim Investigational Site
New Britain, Connecticut, United States
Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
Boehringer Ingelheim Investigational Site
Chesterfield, Missouri, United States
Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
Boehringer Ingelheim Investigational Site
Hackensack, New Jersey, United States
Boehringer Ingelheim Investigational Site
New York, New York, United States
Boehringer Ingelheim Investigational Site
Staten Island, New York, United States
Boehringer Ingelheim Investigational Site
Philedelphia, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
Boehringer Ingelheim Investigational Site
Charlottesville, Virginia, United States
Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
Boehringer Ingelheim Investigational Site
Roanoke, Virginia, United States
Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Boehringer Ingelheim Investigational Site
Saint John, New Brunswick, Canada
Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1160.162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.